JPH0556332B2 - - Google Patents

Info

Publication number
JPH0556332B2
JPH0556332B2 JP26947384A JP26947384A JPH0556332B2 JP H0556332 B2 JPH0556332 B2 JP H0556332B2 JP 26947384 A JP26947384 A JP 26947384A JP 26947384 A JP26947384 A JP 26947384A JP H0556332 B2 JPH0556332 B2 JP H0556332B2
Authority
JP
Japan
Prior art keywords
compound
acid
oxo
reaction
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP26947384A
Other languages
Japanese (ja)
Other versions
JPS61148142A (en
Inventor
Katsuichi Sakano
Masashi Ooshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP26947384A priority Critical patent/JPS61148142A/en
Publication of JPS61148142A publication Critical patent/JPS61148142A/en
Publication of JPH0556332B2 publication Critical patent/JPH0556332B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は、一般式 (式中R1は低級アルキル基またはヒドロキシ低
級アルキル基を意味し、R2は水素原子またはア
シルオキシル基を意味する)で表されるグリチル
レチン酸誘導体およびその塩に関するものであ
る。 グリチルレチン酸およびその誘導体には抗アレ
ルギー作用、抗炎症作用、抗潰瘍作用等の薬理作
用があることが知られている。本発明者らは、微
生物による化合物の変換に着目し、更に化学的手
法を組み合せて新規なグリチルレチン酸誘導体を
製造し本発明を完成した。これらの新規誘導体に
は上記の如き薬理作用が期待されるほか、スタフ
イロコツカス アウレウスに対する抗菌活性が認
められ、医薬品としての用途が期待される。 本発明の化合物の製造法を反応式で例示する
と、次の如くである。 (式中R1は低級アルキル基またはヒドロキシ低
級アルキル基を意味し、R2は水素原子またはア
シルオキシル基を意味する) グリチルレチン酸から後述の参考例に示すよう
にして、微生物変換と化学的手法を組み合せた方
法で調製したグリチルレチン酸のラクトン誘導体
()を低級アルコール(メタノール、エタノー
ル、n−プロパノール、n−ブタノール等)中或
いはヒドロキシ低級アルコール(エチレングリコ
ール等)中で塩酸を触媒として数時間還流するこ
とにより3,4−セコオレアン−4(23),12−ジ
エン−11−オキソ−3,30−ジオイツク酸(また
はその7β−アセトキシ体)の3−メチルエステ
ル、3−エチルエステル、3−(2−ヒドロキシ
エチル)エステル等がそれぞれ効率良く得られ
る。生成物は、反応液を減圧濃縮した後水を添加
して析出せしめ、これを濾取することにより回収
できる。 本発明の原料として使用する化合物()は次
式に示す反応で調製される。 (式中R2′は水素原子またはヒドロキシル基を意
味する) すなわち、グリチルレチン酸()にチヤイニ
ア アンチビオチカIFO 12246(Chainia antibio
−tica)の培養菌体を触媒としてリン酸緩衝液中
で好気的条件下に反応させるとA環の酸化的開裂
および7位のヒドロキシル化反応が起り、化合物
()、(式中R2′は水素原子またはヒドロキシル
基)が生成す。本菌はこれを例えば培地A(第1
表参照)を用いて、28℃で深部培養すると化合物
()におけるA環の酸化的開裂反応と7位のヒ
ドロキシル化反応とを同時に行なう能力が現れ
る。また例えば培地B(第1表参照)を用いて28
℃で深部培養すると化合物()におけるA環の
酸化的開裂反応が強く現われる。したがつてこの
性質を巧みに利用すれば化合物()から所望の
化合物()(式中R2′は水素原子またはヒドロキ
シル基)を有利に調製することが出来る。 生成した化合物()は反応液から例えば酢酸
エチルまたは酢酸エチルとn−ブタノールの混合
溶媒等で抽出し、抽出物をシリカゲルカラムクロ
マトグラフイーに供する等の処理によりそれぞれ
単離精製することができる。 化合物()をラクトン化し、化合物()と
するには、化合物()をピリジン中で無水酢酸
と処理するのが適当である。反応温度は室温付近
が適当であり、無水酢酸は化合物()に対して
大過剰用いる。生成した化合物()は反応液に
水を添加して析出させ単離することができる。
The present invention is based on the general formula (In the formula, R 1 means a lower alkyl group or a hydroxy lower alkyl group, and R 2 means a hydrogen atom or an acyloxyl group) and a salt thereof. Glycyrrhetinic acid and its derivatives are known to have pharmacological effects such as antiallergic, antiinflammatory, and antiulcer effects. The present inventors focused on the conversion of compounds by microorganisms and further combined chemical methods to produce a novel glycyrrhetinic acid derivative and completed the present invention. These new derivatives are expected to have the above-mentioned pharmacological effects, and have also been found to have antibacterial activity against Staphylococcus aureus, and are expected to be used as pharmaceuticals. The method for producing the compound of the present invention is illustrated by the following reaction formula. (In the formula, R 1 means a lower alkyl group or a hydroxy lower alkyl group, and R 2 means a hydrogen atom or an acyloxyl group.) From glycyrrhetinic acid, microbial conversion and chemical methods are used as shown in the reference examples below. A lactone derivative of glycyrrhetinic acid () prepared by a method combining the above is refluxed for several hours in a lower alcohol (methanol, ethanol, n-propanol, n-butanol, etc.) or a hydroxyl lower alcohol (ethylene glycol, etc.) using hydrochloric acid as a catalyst. By doing so, 3-methyl ester, 3-ethyl ester, 3-( 2-hydroxyethyl) ester and the like can be obtained efficiently. The product can be recovered by concentrating the reaction solution under reduced pressure, adding water to precipitate it, and collecting it by filtration. The compound () used as a raw material in the present invention is prepared by the reaction shown in the following formula. (In the formula, R 2 ' means a hydrogen atom or a hydroxyl group.) In other words, chainia antibiotica IFO 12246 is added to glycyrrhetinic acid ().
-tica) as a catalyst in a phosphate buffer under aerobic conditions, oxidative cleavage of the A ring and hydroxylation reaction at the 7-position occur, resulting in the compound (), (in the formula R 2 ' is a hydrogen atom or a hydroxyl group) is generated. This bacterium uses this, for example, in medium A (first
When the compound (see table) is incubated at 28°C in deep water, the ability to simultaneously carry out the oxidative cleavage reaction of the A ring and the hydroxylation reaction at the 7-position in compound () appears. Alternatively, for example, using medium B (see Table 1),
When cultured in deep water at ℃, the oxidative cleavage reaction of the A ring in compound () appears strongly. Therefore, by skillfully utilizing this property, a desired compound () (in the formula, R 2 ' is a hydrogen atom or a hydroxyl group) can be advantageously prepared from compound (). The produced compound () can be extracted from the reaction solution with, for example, ethyl acetate or a mixed solvent of ethyl acetate and n-butanol, and the extract can be isolated and purified by a treatment such as subjecting it to silica gel column chromatography. To lactonize compound () to give compound (), it is appropriate to treat compound () with acetic anhydride in pyridine. The reaction temperature is suitably around room temperature, and acetic anhydride is used in large excess relative to compound (). The generated compound () can be isolated by adding water to the reaction solution to precipitate it.

【表】 実施例 (イ) 3,4−セコオレアン−12−エン−11−オキ
ソ−4−ヒドロキシ−3,30−ジオイツク酸、
3,4−ラクトン(:R2が水素原子)250mg
をエタノール50mlに溶解し、これに濃塩酸0.1
mlを加え4時間還流した。放冷後反応液を減圧
濃縮し、濃縮液に徐々に水を加えてゆくと白色
の沈殿が生成してくるのでこれを濾別し、充分
水洗すると3,4−セコオレアン−4(23),12
−ジエン−11−オキソ−3,30ジオイツク酸3
−エチルエステル(I:R1がエチル基、R2
水素原子)が無色粉末として248mg得られた。
この化合物の物性は次のとおりである。 (1) FD−Massスペクトル(m/z)512(M+) (2) 1Hnmrスペクトル(CDCl3,90MHz)δppm
(TMS) 0.86,1.19,1.19,1.23,1.40,1.76(各々3H,
s),4.08(2H,q,−COOCH2 −),4.70,4.90
(各々1H,brs,C=CH2 )5.73(1H,s,12位
H) (ロ) 同様にして3,4−セコオレアン−12−エン
−11−オキソ−4−ヒドロキシ−3,30−ジオ
イツク酸3,4−ラクトン100mgを塩酸を触媒
としてメタノールと還流することにより3,4
−セコオレアン4(23),12−ジエン−11−オキ
ソ−3,30−ジオイツク酸3−メチルエステル
が無色粉末として94mg得られた。この化合物の
物性は次の通りである。 (1) FD−Massスペクトル(m/z)498(M+) (2) 1Hnmrスペクトル(CDCl3,90MHz)δppm
(TMS) 0.86,1.18,1.18,1.24,1.40,1.76(各々3H,
s),3.62(3H,s,−COOCH3 ),4.70,4.90
(各々1H,brs,C=CH2 )5.74(1H,s,12位
H) (3) 13Cnmrスペクトル(CDCl3)δppm(TMS) 174.4(s,C3位),146.6(s,C4位),128.3(d,
C12位),169.5(s,C13位),114.2(t,C23位 C
CH2 ),182.4(s,C30位) (ハ) 同様にして3,4−セコオレアン−12−エン
−11−オキソ−4−ヒドロキシ−3,30−ジオ
イツク酸3,4−ラクトン100mgを塩酸を触媒
としてn−プロパノールと還流することにより
3,4−セコオレアン−4(23),12−ジエン−
11−オキソ−3,30−ジオイツク酸3−n−プ
ロピルエステルが無色粉末として60mg得られ
た。この化合物の物性は次の通りである。 (1) FD−MaSSスペクトル(m/z)526(M+) (2) 1Hnmrスペクトル(CDCl3,90MHz)δppm
(TMS) 0.87,1.19,1.19,1.24,1.41,1.77(各々3H,
s),3.99(2H,t,−COOCH2 −),4.71,4.91
(各々1H,brs,C=CH2 ),5.74(1H,s,12位
H) (ニ) 同様にして3,4−セコオレアン−12−エン
−11−オキソ−4−ヒドロキシ−3,30−ジオ
イツク酸3,4−ラクトン100mgを塩酸を触媒
としてn−ブタノールと還流するとにより3,
4−セコオレアン−4(23),12−ジエン−11−
オキソ−3,30−ジオイツク酸3−n−ブチル
エステルが無色粉末として101mg得られた。こ
の化合物の物性は次の通りである。 (1) FD−Massスペクトル(m/z)540(M+) (2) 1Hnmrスペクトル(CDCl3,90MHz)δppm
(TMS) 0.86,1.18,1.18,1.24,1.40,1.76(各々3H,
s),4.02(2H,t,−COOCH2 −),4.70,4.90
(各々1H,brs,C=CH2 )5.73(1H,s,12位−
H) (ホ) 同様にして3,4−セコオレアン−12−エン
−11−オキソ−4−ヒドロキシ−3,30−ジオ
イツク酸3,4−ラクトン200mgを塩酸を触媒
としてエチレングリコールと120〜130℃に加熱
することにより3,4−セコオレアン−4
(23),12−ジエン−11−オキソ−3,30−ジオ
イツク酸3−(2−ヒドロキシエチル)エステ
ル(I:R1が2−ヒドロキシエチル基、R2
水素原子)が無色粉末として45mg得られた。こ
の化合物の物性は次の通りである。 (1) FD−Massスペクトル(m/z)528(M+) (2) 1Hnmrスペクトル(CDCl3,9MHz)δppm
(TMS) 0.86,1.18,1.18,1.24,1.41,1.76(各々3H,
s),3.77,4.13(各々2H,m,−COOCH2CH2
OH),4.70,4.90(各々1H,brs,C=CH2 ),
5.73(1H,s,12位H) (ヘ) 同様にして3,4−セコオレアン−12−エン
−11−オキソ−4,7β−ジヒドロキシ−3,
30−ジオイツク酸3,4−ラクトン7−アセテ
ート(:R2がアセトキシル基)260mgを塩酸
を触媒としてメタノールと還流することにより
3,4−セコオレアン−4(23),12−ジエン−
11−オキソ−7β−ヒドロキシ−3,30−ジオ
イツク酸7−アセテート 3−メチルエステルが無色粉末として230mg
得られた。この化合物の物性は次の通りであ
る。 (1) FD−Massスペクトル(m/z)556(M+) (2) 1Hnmrスペクトル(CDCl3,90MHz)δppm
(TMS) 0.86,1.19,1.24,1.29,1.47,1.75(各々3H,
s),2.02(3H,s,−OCOCCH3 ),3.62(3H,
s,COOCH3 )4.71,4.93(各々1H,brs,C=
CH2),5.28(1H,m,7位H),5.78(1H,s,
12位H) 3 13Cnmrスペクトル(CDCl3)δppm(TMS) 174.0(s,C3位),144.5(s,C4位),73.0(d,
C7)位),128.5(d,C12位),169.0(s,C13位),
115.2(t,C23位 C=CH2 )181.6(s,C30位) (ト) 同様にして3,4−セコオレアン−12−エン
−11−オキソ−4,7β−ジヒドロキシ−3,
30−ジオイツク酸3,4−ラクトン7−アセテ
ート160mgを塩酸を触媒としてエタノールと還
流することにより3,4−セコオレアン−4
(23),12−ジエン−11−オキソ−7β−ヒドロ
キシ−3,30−ジオイツク酸7−アセテート3
−エチルエステルが無色粉末として166mg得ら
れた。この化合物の物性は次の通りである。 (1) FD−Massスペクトル(m/z)570(M+) (2)1Hnmrスペクトル(CDCl3、90MHz)δppm
(TMS)0.86,1.20,1.23,1.30,1.48,1.76(各々
3H,s),2.02(3H,s,−OCOCH3 ),4.08(2H,
q,−COO−CH2 −),4.72,4.94(各々1H,brs,
C=CH2 ),5.28(1H,m,7位H),5.79(1H,
s,12位H) 参考例 培地Aをを100ml含んだ500ml溶坂口フラスコに
チヤイニア アンチビオチカIFO12246を斜面培
養から接種し、28℃で4日間振盪培養して種培養
液とした。この種培養液を培地Bを100mlずつ含
んだ坂口フラスコ55本にそれぞれ2.0mlずつ接種
し、28℃で3日間振盪培養した。本培養液を遠心
分離して集めた菌体にPH7.5の0.1Mリン酸緩衝液
を加えて全体容量をを4.0とした。 本液にツイーン80を8.0mlとグリチルレチン酸
を2.00g添加し、充分撹拌した後100mlずつ40本
の坂口フラスコに分注し、28℃で20時間振盪反応
した。反応終了後反応液を一括して回収し、PHを
4.0〜4.5に調製し、反応生成物を酢酸エチル3.0
で抽出した。抽出液は充分水洗した後減圧濃縮し
濃縮物1.8gを得た。これをシリカゲルカラムク
ロマトグラフイーにかけ(展開溶媒、ベンゼン/
酢酸エチル/酢酸=10/10/1)、反応生成物の
分離を行ない、更にメタノールと水から再結晶す
ることにより、3,4−セコオレアン−12−エン
−11−オキソ−4−ヒドロキシ−3,30−ジオイ
ツク酸(:R2′=H)を無色の結晶性粉末とし
て1.14g得た。融点289〜304℃(分解) また前記と同様にして調製したチヤイニア ア
ンチビオチカIFD12246の種培養液を、培地Aを
100mlずつ含んだ坂口フラスコ60本にそれぞれ2.0
mlずつ接種し28℃で1日間振盪培養した。本培養
液を遠心分離して集めた菌体にPH7.0の0.1Mリン
酸緩衝液を加えて全体容量を6.0とした。 本液にグリチルレチン酸を6.00g添加し、充分
撹拌した後100mlずつ60本の坂口フラスコに分注
し、28℃で24時間振盪反応した。反応終了後反応
液をを一括して回収しPH4.0〜4.5に調製し、反応
生成物を酢酸エチルとn−ブタノールの比が4対
1の混合溶媒6.0で抽出した。抽出液は充分水
洗した後減圧濃縮し、濃縮物5.9gを得た。 これをシリカゲルカラムクロマトグラフイーに
かけ(展開溶媒、ベンゼン/酢酸エチル/酢酸=
8/12/1)、反応生成物の分離を行ない、更に
エタノールと水から再結晶することにより3,4
−セコオレアン−12−エン−11−オキソ−4−ヒ
ドロキシ−3,30−ジオイツク酸(:R2′=H)
を無色結晶性粉末として0.38gおよび3,4−セ
コオレアン−12−エン−11−オキソ−4,7β−
ジヒドロキシ−3,30−ジオイツク酸(:
R2′=OH)を無色板状晶として3.44g得た。融点
296〜310℃(分解) 上述の如くして得た化合物(R2′=H)1.00
gに乾燥ピリジンを6.7mlと無水酢酸を6.7ml添加
し、28℃で1日間放置した。反応終了後反応液に
徐々に水を加えてゆくこと無色の結晶性の沈殿が
生成してくるのでこれを濾取し充分水洗すること
により3,4−セコオレアン−12−エン−11−オ
キソ−4−ヒドロキシ−3,30−ジオイツク酸
3,4−ラクトン(:R2=H)を無色結晶性
粉末として0.95gを得た。融点266〜270℃ またこれと同様の方法で一般式()におい
て、R2がヒドロキシル基の化合物1.00gから3,
4−セコオレアン−12−エン−11−オキソ−4,
7β−ジヒドロキシ−3,30−ジオイツク酸3,
4−ラクトン7−アセテート(:R2
OCOCH3)を無色結晶性粉末として1.02g得た。
融点214〜220℃
[Table] Example (a) 3,4-secoolean-12-ene-11-oxo-4-hydroxy-3,30-dioyscinic acid,
3,4-lactone ( R2 is hydrogen atom) 250mg
Dissolve in 50 ml of ethanol and add 0.1 ml of concentrated hydrochloric acid to this.
ml was added and refluxed for 4 hours. After cooling, the reaction solution was concentrated under reduced pressure, and water was gradually added to the concentrated solution. A white precipitate was formed, which was filtered and washed thoroughly with water to obtain 3,4-secooleane-4 (23), 12
-diene-11-oxo-3,30 dioxic acid 3
248 mg of -ethyl ester (I: R 1 is an ethyl group, R 2 is a hydrogen atom) was obtained as a colorless powder.
The physical properties of this compound are as follows. (1) FD-Mass spectrum (m/z) 512 (M + ) (2) 1 Hnmr spectrum (CDCl 3 , 90MHz) δppm
(TMS) 0.86, 1.19, 1.19, 1.23, 1.40, 1.76 (3H, respectively
s), 4.08 (2H, q, −COO CH 2 −), 4.70, 4.90
(1H, brs, C= CH 2 respectively) 5.73 (1H, s, H at the 12th position) By refluxing 100 mg of acid 3,4-lactone with methanol using hydrochloric acid as a catalyst, 3,4-lactone
-Sequooleane 4(23),12-diene-11-oxo-3,30-dioic acid 3-methyl ester was obtained as a colorless powder in an amount of 94 mg. The physical properties of this compound are as follows. (1) FD-Mass spectrum (m/z) 498 (M + ) (2) 1 Hnmr spectrum (CDCl 3 , 90MHz) δppm
(TMS) 0.86, 1.18, 1.18, 1.24, 1.40, 1.76 (3H, respectively
s), 3.62 (3H, s, -COO CH 3 ), 4.70, 4.90
(1H, brs, C = CH 2 respectively) 5.74 (1H, s, H at 12th position) (3) 13 Cnmr spectrum (CDCl 3 ) δppm (TMS) 174.4 (s, C 3rd position), 146.6 (s, C 4 ), 128.3(d,
C 12th place), 169.5 (s, C 13th place), 114.2 (t, C 23rd place C)
= CH 2 ), 182.4 (s, C 30th position) (c) In the same manner, 100 mg of 3,4-secoolean-12-ene-11-oxo-4-hydroxy-3,30-dioytuccinic acid 3,4-lactone was added. By refluxing with n-propanol using hydrochloric acid as a catalyst, 3,4-secooleane-4(23),12-diene-
60 mg of 11-oxo-3,30-dioic acid 3-n-propyl ester was obtained as a colorless powder. The physical properties of this compound are as follows. (1) FD-MaSS spectrum (m/z) 526 (M + ) (2) 1 Hnmr spectrum (CDCl 3 , 90MHz) δppm
(TMS) 0.87, 1.19, 1.19, 1.24, 1.41, 1.77 (3H, respectively
s), 3.99 (2H, t, -COO CH 2 -), 4.71, 4.91
(1H, brs, C= CH 2 respectively), 5.74 (1H, s, H at position 12) (d) Similarly, 3,4-secoolean-12-ene-11-oxo-4-hydroxy-3,30- When 100 mg of dioic acid 3,4-lactone is refluxed with n-butanol using hydrochloric acid as a catalyst, 3,
4-Sequoolean-4(23),12-diene-11-
101 mg of oxo-3,30-dioic acid 3-n-butyl ester was obtained as a colorless powder. The physical properties of this compound are as follows. (1) FD-Mass spectrum (m/z) 540 (M + ) (2) 1 Hnmr spectrum (CDCl 3 , 90MHz) δppm
(TMS) 0.86, 1.18, 1.18, 1.24, 1.40, 1.76 (3H, respectively
s), 4.02 (2H, t, -COO CH 2 -), 4.70, 4.90
(1H, brs, C = CH 2 ) 5.73 (1H, s, 12th position -
H) (E) In the same manner, 200 mg of 3,4-lactone 3,4-secoolean-12-ene-11-oxo-4-hydroxy-3,30-dioic acid was mixed with ethylene glycol using hydrochloric acid as a catalyst at 120 to 130°C. 3,4-Secooleane-4 by heating to
(23), 12-diene-11-oxo-3,30-dioic acid 3-(2-hydroxyethyl) ester (I: R 1 is 2-hydroxyethyl group, R 2 is hydrogen atom) 45 mg as colorless powder Obtained. The physical properties of this compound are as follows. (1) FD-Mass spectrum (m/z) 528 (M + ) (2) 1 Hnmr spectrum (CDCl 3 , 9MHz) δppm
(TMS) 0.86, 1.18, 1.18, 1.24, 1.41, 1.76 (3H, respectively
s), 3.77, 4.13 (respectively 2H, m, −COO CH 2 CH 2
OH), 4.70, 4.90 (1H, brs, C = CH 2 ),
5.73 (1H, s, H at position 12) (f) Similarly, 3,4-secoolean-12-ene-11-oxo-4,7β-dihydroxy-3,
3,4-Secooleane-4(23),12 - diene-
230 mg of 11-oxo-7β-hydroxy-3,30-diotuccinic acid 7-acetate 3-methyl ester as colorless powder
Obtained. The physical properties of this compound are as follows. (1) FD-Mass spectrum (m/z) 556 (M + ) (2) 1 Hnmr spectrum (CDCl 3 , 90MHz) δppm
(TMS) 0.86, 1.19, 1.24, 1.29, 1.47, 1.75 (3H, respectively
s), 2.02 (3H, s, -OCOC CH 3 ), 3.62 (3H,
s, COO CH 3 ) 4.71, 4.93 (1H, brs, C= respectively
CH 2 ), 5.28 (1H, m, H at 7th position), 5.78 (1H, s,
12th position H) 3 13 Cnmr spectrum (CDCl 3 ) δppm (TMS) 174.0 (s, C 3rd position), 144.5 (s, C 4th position), 73.0 (d,
C 7th place), 128.5 (d, C 12th place), 169.0 (s, C 13th place),
115.2 (t, C 23rd position C= CH 2 ) 181.6 (s, C 30th position) (g) Similarly, 3,4-secoolean-12-ene-11-oxo-4,7β-dihydroxy-3,
3,4-Secooleane-4 was obtained by refluxing 160 mg of 30-diotuccinic acid 3,4-lactone 7-acetate with ethanol using hydrochloric acid as a catalyst.
(23), 12-diene-11-oxo-7β-hydroxy-3,30-diotuccinic acid 7-acetate 3
-166 mg of ethyl ester was obtained as a colorless powder. The physical properties of this compound are as follows. (1) FD-Mass spectrum (m/z) 570 (M + ) (2) 1 Hnmr spectrum (CDCl 3 , 90MHz) δppm
(TMS) 0.86, 1.20, 1.23, 1.30, 1.48, 1.76 (each
3H, s), 2.02 (3H, s, -OCO CH 3 ), 4.08 (2H,
q, −COO− CH 2 −), 4.72, 4.94 (1H, brs, respectively
C= CH 2 ), 5.28 (1H, m, H at 7th position), 5.79 (1H,
s, 12th H) Reference Example A 500 ml Sakaguchi flask containing 100 ml of medium A was inoculated with Chiainia antibiotica IFO12246 from a slant culture, and cultured with shaking at 28°C for 4 days to obtain a seed culture. 2.0 ml of this seed culture solution was inoculated into 55 Sakaguchi flasks each containing 100 ml of medium B, and cultured with shaking at 28° C. for 3 days. The main culture solution was centrifuged and 0.1M phosphate buffer of PH7.5 was added to the collected bacterial cells to bring the total volume to 4.0. To this solution were added 8.0 ml of Tween 80 and 2.00 g of glycyrrhetinic acid, and after thorough stirring, the mixture was dispensed into 40 Sakaguchi flasks in 100 ml portions and reacted with shaking at 28° C. for 20 hours. After the reaction is complete, collect the reaction solution all at once and adjust the pH.
4.0 to 4.5 and the reaction product to ethyl acetate 3.0
Extracted with. The extract was thoroughly washed with water and then concentrated under reduced pressure to obtain 1.8 g of a concentrate. This was subjected to silica gel column chromatography (developing solvent, benzene/
3,4-secoolean-12-ene-11-oxo-4-hydroxy-3 was obtained by separating the reaction product and recrystallizing it from methanol and water. , 30-Diotsuccinic acid (:R 2 '=H) was obtained as a colorless crystalline powder in an amount of 1.14 g. Melting point: 289-304°C (decomposed) In addition, a seed culture of Chiainia antibiotica IFD12246 prepared in the same manner as above was mixed with medium A.
2.0 each for 60 Sakaguchi flasks containing 100 ml each.
ml each was inoculated and cultured with shaking at 28°C for 1 day. The main culture solution was centrifuged and 0.1M phosphate buffer of PH7.0 was added to the collected bacterial cells to make the total volume 6.0. 6.00 g of glycyrrhetinic acid was added to this solution, and after thorough stirring, the mixture was dispensed into 60 Sakaguchi flasks in 100 ml portions, and reacted with shaking at 28° C. for 24 hours. After the reaction was completed, the reaction solution was collected all at once and the pH was adjusted to 4.0 to 4.5, and the reaction product was extracted with a mixed solvent of 6.0 ethyl acetate and n-butanol in a ratio of 4:1. The extract was thoroughly washed with water and then concentrated under reduced pressure to obtain 5.9 g of a concentrate. This was subjected to silica gel column chromatography (developing solvent, benzene/ethyl acetate/acetic acid =
8/12/1), the reaction product was separated and further recrystallized from ethanol and water to obtain 3,4
-Sequoolean-12-ene-11-oxo-4-hydroxy-3,30-dioic acid (:R 2 ′=H)
0.38 g as a colorless crystalline powder and 3,4-secoolean-12-ene-11-oxo-4,7β-
Dihydroxy-3,30-dioic acid (:
3.44 g of R 2 '=OH) was obtained as colorless plate crystals. melting point
296-310°C (decomposition) Compound obtained as above (R 2 ′=H) 1.00
6.7 ml of dry pyridine and 6.7 ml of acetic anhydride were added to the mixture, and the mixture was left at 28°C for 1 day. After the reaction is completed, water is gradually added to the reaction solution. A colorless crystalline precipitate is formed, which is collected by filtration and thoroughly washed with water to obtain 3,4-secoolean-12-ene-11-oxo- 0.95 g of 4-hydroxy-3,30-dioic acid 3,4-lactone (:R 2 =H) was obtained as a colorless crystalline powder. Melting point: 266-270°C In a similar manner, in the general formula (), from 1.00 g of a compound in which R 2 is a hydroxyl group, 3,
4-sequoolean-12-ene-11-oxo-4,
7β-dihydroxy-3,30-dioitsucic acid 3,
4-lactone 7-acetate (:R 2 =
1.02 g of OCOCH 3 ) was obtained as a colorless crystalline powder.
Melting point 214-220℃

Claims (1)

【特許請求の範囲】 1 一般式 (式中R1は低級アルキル基またはヒドロキシ低
級アルキル基を意味し、R2は水素原子またはア
シルオキシル基を意味する)で表わされるグリチ
ルレチン酸誘導体およびその塩
[Claims] 1. General formula (In the formula, R 1 means a lower alkyl group or a hydroxy lower alkyl group, and R 2 means a hydrogen atom or an acyloxyl group.) Glycyrrhetinic acid derivatives and their salts
JP26947384A 1984-12-20 1984-12-20 Seco-type derivative of glycyrrhezic acid Granted JPS61148142A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP26947384A JPS61148142A (en) 1984-12-20 1984-12-20 Seco-type derivative of glycyrrhezic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26947384A JPS61148142A (en) 1984-12-20 1984-12-20 Seco-type derivative of glycyrrhezic acid

Publications (2)

Publication Number Publication Date
JPS61148142A JPS61148142A (en) 1986-07-05
JPH0556332B2 true JPH0556332B2 (en) 1993-08-19

Family

ID=17472926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26947384A Granted JPS61148142A (en) 1984-12-20 1984-12-20 Seco-type derivative of glycyrrhezic acid

Country Status (1)

Country Link
JP (1) JPS61148142A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519008A (en) * 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
CN112608800A (en) * 2020-12-17 2021-04-06 江苏耐雀生物工程技术有限公司 Handmade soap with anti-allergy function and preparation method thereof

Also Published As

Publication number Publication date
JPS61148142A (en) 1986-07-05

Similar Documents

Publication Publication Date Title
US4399282A (en) Camptothecin derivatives
JPH0710876B2 (en) Improved method for producing macrolide derivative
US11384116B2 (en) Methods of making cholic acid derivatives and starting materials therefor
HU198938B (en) Process for producing podophyllotoxin and podophyllotoxin derivatives
EP0418925B1 (en) Method of producing (S)-4-hydroxymethyl-gamma-lactone
AU771214B2 (en) Process for the isolation of pseudomonic acid a from pseudomonic acid complex-containing culture broth
FR2473519A1 (en) TERPENOIDS CONTAINING TWO FUNCTIONAL GROUPS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
JPH0556332B2 (en)
SU860708A1 (en) Method of preparing steroids
JPH058179B2 (en)
JPH0121146B2 (en)
JPH06256278A (en) Optically active alpha-carbamoylalkanoic acid derivative and its production
US6051721A (en) Ring E-modified analogues of(-)-podophyllotoxin and etoposide and a method for their synthesis
US4528372A (en) N-Phthalidyl-5-fluorouracils
EP0469480A2 (en) Process for stereoselective preparation of 5-substituted delta-lactones and their use
JPH0362718B2 (en)
WO1996006829A1 (en) 1,4-dihydropyridine derivative
JPS6258351B2 (en)
JP2700818B2 (en) Exo-type 3 ', 4'-O-benzylidene-3 "-demethylchartlucin and salts thereof
US2694068A (en) Ag-desoxymorphine compounds and proc-
JPH0362717B2 (en)
US4188329A (en) Intermediates for the preparation of prostaglandins and prostaglandin analogs from a mold metabolite
JP2001523259A (en) 4-aza-steroids
JP2675569B2 (en) Method for producing 2,3-dihydrobenzofuran derivative
JP3142273B2 (en) Production intermediate of antibiotic MI43-37F11